2019年与2020年乳腺癌放射治疗使用情况比较
本研究基于商业和 Medicare Advantage 健康计划的事先授权订单数据,比较2019年与2020年肿块切除术后90天内放疗订单率及大分割放疗占比。结果显示2020年放疗订单率低于2019年(45.6% vs 47.7%,P=0.048),而大分割放疗占比高于2019年(79.0% vs 75.3%,P=0.011)。
要点
- 2020年肿块切除术后90天内放疗订单率为45.6%(1944/4263),低于2019年的47.7%(2200/4610),P=0.048。
- 2020年放疗订单中大分割放疗占79.0%(1261/1597),高于2019年的75.3%(1387/1843),P=0.011。
- 调整分析显示2020年第一季度肿块切除订单患者接受后续放疗的比值比低于2019年同期(OR 0.84,95%CI 0.71-0.99)。
核心结论
- 在所研究人群中,医生2020年较2019年更少在肿块切除术后开具放疗订单,且开具时更倾向于大分割放疗。
研究设计与样本
- 回顾性分析2019年和2020年商业及 Medicare Advantage 健康计划的事先授权订单数据,纳入肿块切除术后90天内是否有放疗订单及分次方案类型,采用χ2检验和多因素logistic回归调整年龄、城乡、收入、地区、机构学术属性及医院属性。
主要发现
- 2019年纳入的肿块切除订单中47.7%(2200/4610)在90天内后续有放疗订单,2020年为45.6%(1944/4263),P=0.048。
- 符合研究定义的放疗订单中,2019年大分割放疗占75.3%(1387/1843),2020年占79.0%(1261/1597),P=0.011。
- 调整分析显示,2020年第一季度肿块切除订单患者后续接受放疗订单的比值比为0.84(95%CI 0.71-0.99),相对于2019年第一季度订单患者。
- 调整分析同样发现疫情期间大分割放疗使用增加的显著证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The COVID-19 pandemic disrupted medical care. Little is known about how radiation therapy (RT) ordering behavior changed during the pandemic. This study examined (1) whether there was a change in the rate at which orders for lumpectomy were followed by orders for RT and (2) whether there was a change in the percentage of RT orders for hypofractionated (HF) RT rather than conventionally fractionated (CF) RT. METHODS AND MATERIALS: Prior authorization order data from 2019 and 2020, pertaining to patients with commercial and Medicare Advantage health plans, were reviewed to determine whether patients had an order for RT in the 90 days after lumpectomy and if it was for CF or HF RT. Univariate analyses were conducted using χ2 tests, and adjusted analyses were conducted using multivariate logistic regression, controlling for patient age, urbanicity, local median income, region, if the lumpectomy facility was academic, and if the lumpectomy facility was a hospital. RESULTS: In 2019, 47.7% of included lumpectomy orders (2200/4610) were followed by an RT order within 90 days, in contrast to 45.6% (1944/4263) in 2020 (P = .048). Of the RT orders meeting this study's definition of CF or HF, 75.3% of orders placed in 2019 (1387/1843) and 79.0% of orders placed in 2020 (1261/1597) were for HF (P = .011). Adjusted analysis found patients receiving a lumpectomy order in the first quarter of 2020 had significantly reduced odds (odds ratio, 0.84; 95% CI, 0.71-0.99) of receiving an order for RT after lumpectomy, relative to those with orders placed in the first quarter of 2019. Adjusted analysis likewise found significant evidence of increased use of HF RT during the pandemic. CONCLUSIONS: In the population examined, physicians were less likely to order RT after lumpectomy in 2020 than in 2019, and if they did, were more likely to order HF RT.
引用
- Powell AC, Long JW, Bhatnagar AK, et al. Use of Radiation Therapy for the Treatment of Breast Cancer in 2019 Versus 2020. Adv Radiat Oncol. 2023. PMID: 38778830. doi:10.1016/j.adro.2023.101435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。